Posted by Michael Wonder on 11 Mar 2026
PHARMAC to fund life‑changing treatments for children with cystic fibrosis
11 March 2026 - PHARMAC will fund new treatment options for people living with cystic fibrosis from 1 April 2026.
The decision includes:
- Widening access to Trikafta and Kalydeco for all people with eligible mutations
- Funding Alyftrek for the first time for people with eligible mutations
